UHRF1's role in liver regrowth
Regulation of Liver Regeneration by UHRF1
['FUNDING_R01'] · NEW YORK UNIVERSITY · NIH-11330233
Looks at whether changes in the UHRF1 protein and the liver's epigenetic markings help livers, including older ones, rebuild themselves after injury.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11330233 on ClinicalTrials.gov |
What this research studies
From a patient's point of view, scientists are studying how the liver's 'on/off' marks in DNA and chromatin help resting liver cells rapidly switch on repair programs. They use cell and animal models where the epigenetic regulator UHRF1 is removed in liver cells to see how DNA methylation, histone marks (like H3K27me3 and H3K4me3), and transposable elements change during regeneration. The team tracks how these changes affect whether hepatocytes re-enter the cell cycle and restore liver tissue. Findings aim to reveal molecular switches that could be targeted to improve healing in damaged or aging livers.
Who could benefit from this research
Good fit: People with recent liver injury, chronic liver disease, or older adults with reduced regenerative capacity would be the patients most likely to be candidates for future related studies.
Not a fit: People without liver conditions or those with end-stage cirrhosis requiring transplant may not see direct benefit from this line of research.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost liver repair and help patients with acute or chronic liver injury recover faster.
How similar studies have performed: Prior work has shown epigenetic marks shift during liver regeneration, but targeting UHRF1 and its effects on DNA methylation is a relatively new and less-tested approach.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SADLER EDEPLI, KIRSTEN C — NEW YORK UNIVERSITY
- Study coordinator: SADLER EDEPLI, KIRSTEN C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.